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ABSTRACT
Two amplification tests for the diagnosis of
Chlamydia trachomatis infection, namely the ligase
chain reaction (LCx) and the strand displacement
assay (ProbeTec), were compared using samples
from 1183 patients at sexually transmitted disease
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clinics. The overall prevalence of positive results
was 8.0%, with agreement between the two
assays of 98.8%. For endocervical, urethral and
male urine samples, agreement was 99.3%, 99.4%
and 97.7%, respectively. For ten discrepant sam-
ples, alternative amplification assays suggested
that the LCx and ProbeTec assays gave erroneous
results in six and four cases, respectively. Inhibi-
tion of amplification was observed with three
(0.25%) urine specimens.
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Chlamydia trachomatis is the most common bacter-
ial cause of sexually transmitted disease in the
Western world [1]. Untreated, acute chlamydial
infections, such as cervicitis and urethritis, may be
complicated by pelvic inflammatory disease and
infertility, chronic abdominal pain, and reactive
arthritis [2]. Since both symptomatic and asymp-
tomatic cases may be at equal risk of suffering
these complications, the important role of early
laboratory diagnosis, screening programmes and
contact tracing is well-recognised [3].
In Sweden, following a decline during the
previous decade, the incidence of C. trachomatis
infection increased from 13 800 cases in 1997 to
26 800 cases in 2003 (i.e., from 160 to 300
cases ⁄ 100 000 inhabitants) (Swedish Institute for
Infectious Disease Control; http://www.smit-
tskyddsinstitutet.se). Altered sexual behaviour
may largely account for these trends, but
increased use of newer diagnostic techniques, in
particular nucleic acid amplification tests
(NAATs), may have contributed to the higher
incidence found during the last few years.
A higher sensitivity of NAATs compared to
culture for the laboratory diagnosis of C. tracho-
matis has been well-documented [4,5]. Further-
more, diagnosis by NAATs of C. trachomatis
infection in urine or vaginal specimens appears
to be almost as acceptable as in urethral and
endocervical samples [6–8], although reduced
sensitivity with female urine samples, compared
to endocervical swabs, has been reported [9,10].
The present study examined the performance
of two commercial NAATs, namely the ligase
chain reaction and the strand displacement assay.
Both rely on the detection of a C. trachomatis-
specific cryptic plasmid. Two venereological clin-
ics (Lund and Helsingborg) and four clinics for
adolescents participated in the study. From each
patient, duplicate samples from one site only
were obtained, according to the instructions of the
respective manufacturer (see below). The order of
sampling was changed after an interval of
2 weeks. In total, 1183 consecutive patients were
investigated, with 675 endocervical swabs, 347
male urine samples and 161 male urethral sam-
ples. Patients with symptoms of genital tract
infection, as well as asymptomatic cases, were
included, but were not studied separately, and
the laboratory did not receive any information
regarding the presence or absence of symptoms.
Urine samples were first void, taken in one tube
and then divided into two samples.
The presence of chlamydial DNA was analysed
by ligase chain reaction (LCx Chlamydia trachoma-
tis assay; Abbott Laboratories, North Chicago, IL,
USA) and strand displacement assay (ProbeTec
Chlamydia assay; Becton Dickinson Bioscience
Europe, Meylan, France), according to the manu-
facturers’ guidelines; the LCx assay was generally
performed within 2 days of sampling, whereas
the ProbeTec assay was performed after
2–6 weeks, during which time the samples were
kept frozen at ) 20C. For both methods, a repeat
positive outcome was required for the sample to
be considered positive. No instances of one
positive and one negative result were observed
during the study.
Specimens yielding different outcomes with the
two methods were stored frozen for later testing
at the Department of Clinical Microbiology, Uni-
versity Hospital of Malmo¨, Sweden (K. Persson)
and the Statens Serum Institute, Copenhagen,
Denmark (J. Skov Jensen). In Malmo¨, further
analysis was with the Cobas Amplicor Chlamydia
trachomatis Test (Roche Diagnostic Systems,
Branchburg, NJ, USA), targeting the same cryptic
plasmid as the two assays under investigation,
whereas in Copenhagen, an in-house PCR assay,
targeting 16S ribosomal RNA and including an
internal amplification control, was used. Aliquots
of the discrepant cervical and urethral samples
were referred to these external laboratories.
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Among all 1183 specimens, the overall agree-
ment between the LCx and ProbeTec assays was
98.8%, with 8.0% positive results with either
method. The corresponding figures were 99.3%
and 6.1% for the 675 endocervical samples, 99.4%
and 9.3% for urethral samples, and 97.7% and
11.2% for urine samples (Table 1).
In total, samples from ten patients (Table 2)
gave discrepant results and were tested with two
other amplification assays at the external laborat-
ories. No clinical data were used in these evalu-
ations. Four samples were endocervical, one was
urethral, and five were urine. Following further
analysis, it was concluded that the the LCx assay
gave five false-positive results, compared to one
false-positive result with the ProbeTec assay;
however, false-negative results with the ProbeTec
assay were suspected in three cases, compared
with one case with the LCx assay. Specimen no. 4
(Table 2) was considered to be positive, since it
gave a positive result with both the LCx and
Amplicor assays.
The superiority of NAATs over culture has
been established in a number of previous stud-
ies. Thus, the sensitivity of culture compared
with ligase chain reaction, one of the tests used
in this study, was reported to be no more than
80% for endocervical samples and considerably
less for urethral samples [11,12], while culture
for detection of C. trachomatis in urine is known
to be inadequate [13]. In the present study of
almost 1200 consecutive patients, 98.8% agree-
ment was obtained between the LCx and Probe-
Tec assays, with agreement among endocervical
and urethral specimens, which required separate
sampling for the two assays, being even higher
than among urine specimens. The high agree-
ment observed might be because both assays
detect a common target, namely a cryptic multi-
copy plasmid specific to C. trachomatis [14].
Theoretically, this could imply a problem of
specificity, in that false-positive results might be
undetected, although the specificity of the ligase
chain reaction has been amply documented in
previous studies, suggesting that such errors are
unlikely to be common [15].
Independent analysis of discrepant samples
indicated one false-negative LCx result and three
false-negative ProbeTec results. One of the latter
samples, as well as two additional samples,
showed non-specific inhibition according to the
manufacturer’s definition. Since an inhibition
control was included in the two independent
NAATs, the alternative conclusion, that the LCx
assay yielded false-positive results, was less
likely. However, the LCx assay was considered
to yield false-positive results with five samples. It
should be emphasised that all these samples were
only weakly positive with the ProbeTec or LCx
assays. It was concluded that repeated defrosting
(on three occasions) of the samples included in
the discrepant analysis did not account for the
negative outcomes, since the results obtained
were in agreement with the initial ProbeTec
results. Overall, the rate of non-specific inhibition,
limited to these three samples, was comparatively
low, which was in agreement with previous
reports [16,17].
In conclusion, the two NAATs, the LCx and
ProbeTec assays, performed almost identically
with respect to the detection of C. trachomatis in
urethral, endocervical and urine samples. These
results agree with a report from the UK [10] that
showed high levels of sensitivity and specificity
for both the strand displacement assay and ligase
chain reaction with endocervical and urine spec-
imens. Efficient contact tracing, combined with
the use of NAATs, may help to reduce the pool of
asymptomatic carriers and decrease the incidence
of chlamydial genital infections. Furthermore, the
Table 2. Analysis of discrepant samples and interpret-
ation
Specimen ⁄
type ProbeTec LCx
Copenhagen
(in-house PCR)a
Malmo¨
(Amplicor)a
Final
interpretation
1 ⁄Urethra – + ND ⁄+ – ⁄+ Positive
2 ⁄Endocervix + – – ⁄ – – ⁄ – Negative
3 ⁄Endocervix – + – ⁄ – – ⁄ – Negative
4 ⁄Endocervix – + – ⁄ – – ⁄+ Positive
5 ⁄Endocervix – + – ⁄ – – ⁄ Negative
6 ⁄Urine – inhib + – – Negative
7 ⁄Urine – inhib + – – Negative
8 ⁄Urine – + – – Negative
9 ⁄Urine – inhib + + – Positive
10 ⁄Urine + – ND + Positive
aResult obtained with ProbeTec and LCx samples, respectively.
inhib, non-specific inhibition as defined by the ProbeTec guidelines; ND, not done.
Table 1. Comparison of LCx and ProbeTec assays for
detection of Chlamydia trachomatis in different specimen
types
Specimen type Total No. positive Prevalencea (%) Agreement (%)
Endocervix 675 41 6.1 99.3
Urethra 161 15 9.3 99.4
Urine (male) 347 39 11.2 99.7
Total 1183 95 8.0 98.8
aSimilar figures were obtained for the LCx and ProbeTec assays.
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reduction in healthcare costs associated with
tubal infertility, including the costs of in-vitro
fertilisation, constitute an important argument for
the use of DNA amplification technology for the
diagnosis of C. trachomatis.
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ABSTRACT
A cross-sectional study was performed in 60
Cuban women of child-bearing age who were
seropositive for human immunodeficiency virus
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